Abstract CT301: SHR-A1811 ± adebrelimab as first-line (1L) treatment for advanced HER2-mutant NSCLC: A randomized phase 2 cohort from a phase 1b/2 study
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Shun Lu, Zhengbo Song, Ziming Li, Haiyong Wang, Yan Yu, Qitao Yu, Shaozhang Zhou, Zhiyong He, Yan Wang, Yiping Zhang, Songyan Han, Rui Meng, Guoqun Zhang, Longhua Sun, Xueqin Chen, Yong Mao, Yongsheng Li, Yongzhong Luo, Kangsheng Gu, Xuhong Min, Bo Jin, Runxiang Yang, Yanqiu Zhao, Liqiang Zhong, Jun Wang, Zhiguo Zhou, Chengzhi Zhou, Kaijun Zhang, Xiaotong Li, Xinjing Ma, Liju Zong, You Li
Institutions: Shanghai Jiao Tong University, Shanghai Chest Hospital, Zhejiang Cancer Hospital, Shandong First Medical University, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Fujian Provincial Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Shanxi Provincial Cancer Hospital, Huazhong University of Science and Technology, First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Nanchang University, Hangzhou Cancer Hospital, Jiangnan University, Wuxi Fourth People's Hospital, Chongqing University, Chongqing Cancer Hospital, Central South University, Hunan Cancer Hospital, Anhui Medical University, First Affiliated Hospital of Anhui Medical University, First Hospital of China Medical University, Henan Cancer Hospital, Second People’s Hospital of Yibin, Hebei Medical University, Fourth Hospital of Hebei Medical University, First Affiliated Hospital of Guangzhou Medical University, Zhongshan People's Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154693597